Simulations Plus (SLP) Successfully Delivers FDA-Funded Project
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St set to open higher as pause in US-Iran hostilities lifts sentiment
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices near one-week low after US, Iran pause fighting over weekend
- Jefferies turns bullish on Ford, GM ahead of earnings, citing stronger margins
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
- Strategy sells MSTR shares, doesn't buy bitcoin
Simulations Plus Successfully Delivers FDA-Funded Project
April 28, 2022 8:30 AM EDTCollaboration with the US FDA and Center for Research on Complex Generics to Establish the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectables
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the completion of a newly funded project from the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG), through a collaboration of its Lixoft and Cognigen divisions, to establish the suitability of... More
